Mylab Discovery Solutions Private Ltd., situated in Pune, which is also the first Indian company to get approval for COVID-19 test units in India, has announced that it has bagged an undisclosed amount from Sakal Media Group’s MD Abhijit Pawar and Adar Poonawalla, CEO – Serum Institute of India.
Additional capital will be deployed for scaling up the production of COVID-19 testing kits and for expansion of cutting edge molecular diagnostic solutions.
Sujit Jain, Director Mylab Discovery Solutions Private Ltd. and Managing Director of Netsurf, Shailendra Kawade, Director Mylab Discovery Solutions Private Ltd. and Hasmukh Rawal, Managing Director Mylab Discovery Solutions Private Ltd., signed a partnership to build a molecular biotechnology company, which will serve humanity in a socially dependable manner.
“This association can impact billions of individuals over the world, particularly India”, commented Hasmukh Rawal and Shailendra Kawade.
Chairman of AP Gobale and MD of Sakal Media Group, Abhijit Pawar quoted, “We are honored to stand by our Prime Minister and our government while supporting them during this difficult time. This partnership will ensure we do our bit to help in this time of crisis.”
A positive impact business solutions organization, AP Globale with interests in differing businesses, including Sakal Media, will support Mylabs to scale its operations in India and worldwide. Abhijit Pawar, Chairman of APG, will join as a board of member in the company.
Mylab Discovery Solutions Pvt. Ltd. is an Indian biotechnology organization offering progressed In-Vitro Diagnostics. The organization offers a wide range of molecular diagnostics services, created in Pune by in-house Research and Development team, helping it to turn into the first Indian company who secured business approval for Covid-19 test kits in India, with 100% concordance results. Previously in May, 2019, Mylab became the India’s first FDA/CDSCO approved producer for RT-PCR based molecular diagnostics kits for quantification and detection of HBV, HCV & HIV. This was trailed by NatSpertTM, Individual Donor Nucleic Acid Amplification Test (ID-NAT) screening kits for hospitals and blood donation centers, thereby turning into the first Asian company and 2nd company worldwide to produce ID-NAT kits approved by regulatory bodies.
Mylab plans to improve disease identification and making it more affordable with state of art technology. To this tune, the company is dealing with advancement of Sample-to-Result lab machine which will robotize the total procedure of complex In-Vitro diagnostics. Home developed R&D organization from India with no collaboration wherein India will be contributing the world in Pharmaceutical drug discovery, Clinical diagnostics, Biomedical exploration, Agri genomics and Animal & food safety. This will make the procedure quick and decrease errors.
Thanks very interesting blog!